Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619811 · ClinicalTrials.gov registry record · NA
Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
A NA study of Gastroesophageal Reflux and Laryngopharyngeal Reflux, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03619811: Completed NA study of Gastroesophageal Reflux and Laryngopharyngeal Reflux, sponsored by University of California, San Diego.
NCT03619811 is a NA study of Gastroesophageal Reflux and Laryngopharyngeal Reflux that has completed, run by University of California, San Diego. The registered enrollment target is 43 participants, below the 2,885-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03619811, a NA study of Gastroesophageal Reflux and Laryngopharyngeal Reflux, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to learn more about reflux associated laryngeal symptoms, and more efficient ways to diagnose and treat this condition.
Primary Outcome
Response will be assessed binary as positive or negative where a positive response is defined by a post-treatment reflux symptom index (RSI) score ≤ 13 and a 33% change from comparator RSI. The minimum value is 0 and the maximum value is 45. The lower the score means less reported symptoms and the higher the score means more reported symptoms.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Reflux Band® Upper Esophageal Sphincter (UES) Assist Device
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2021-06-30 |
| Phase | NA |
What the finished NCT03619811 record still lists
NCT03619811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 2,885-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which Reflux Band® Upper Esophageal Sphincter (UES) Assist Device is the first listed.
NCT03619811 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03619811 about?
NCT03619811 is a clinical study titled "Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease". This study plans to learn more about reflux associated laryngeal symptoms, and more efficient ways to diagnose and treat this condition.
What is the current status of trial NCT03619811?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2018-07-13. Estimated completion is 2021-06-30.
What conditions does trial NCT03619811 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux, Laryngopharyngeal Reflux.
What interventions are being tested in trial NCT03619811?
The interventions under investigation include: Reflux Band® Upper Esophageal Sphincter (UES) Assist Device (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03619811?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03619811 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03619811's enrollment target sits among peer trials
43 25th of 33 higher than 9 of 33 other Gastroesophageal Reflux trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
External UES Band (Shaker Pressure Band) and GERD
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Establishing Pressures at the EGJ During Diaphragmatic Breathing Using High-resolution Esophageal Manometry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI